NR4A1 and neoplasm: Unlike systemic therapy, fully personalized RT has yet to be adopted in the clinical setting (9) as standard clinical-pathological parameters like patient’s age, tumor size, nodal involvement, margin width, hormone receptor status, tumor grade, lymphovascular invasion still drive adjuvant RT.